Variable
|
Grouping
|
Coefficient
|
OR
|
P-value
|
---|
Sex
|
Male
|
Reference
|
Reference
|
Reference
|
Female
|
−0.466
|
0.628
|
0.037
|
Stage
|
I
|
Reference
|
Reference
|
Reference
|
II
|
0.744
|
2.105
|
0.161
|
III
|
1.573
|
4.823
|
0.006
|
IV
|
1.429
|
4.175
|
0.011
|
IPI
|
Low
|
Reference
|
Reference
|
Reference
|
Low-intermediate
|
0.907
|
2.478
|
0.008
|
High-intermediate
|
0.953
|
2.594
|
0.013
|
High
|
1.210
|
3.352
|
0.016
|
KPS
|
≥ 80
|
Reference
|
Reference
|
Reference
|
<80
|
0.734
|
2.084
|
0.014
|
GCB
|
No
|
Reference
|
Reference
|
Reference
|
Yes
|
−0.792
|
0.453
|
0.041
|
CD10
|
Negative
|
Reference
|
Reference
|
Reference
|
Positive
|
−1.144
|
0.318
|
< 0.001
|
Rituximab
|
Not use
|
Reference
|
Reference
|
Reference
|
Use
|
−0.502
|
0.605
|
0.027
|
- IPI international prognostic index, KPS Karnofsky performance status, GCB germinal center B-cell-like lymphoma, CD10 is immunohistochemical indicators